The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“Mutations that are predicted to activate the mammalian D-type cyclin-dependent Rb kinases CDK4 and CDK6 are frequently observed in cancer (Malumbres and Barbacid, 2009;Musgrove et al., 2011).”
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680 · cited 4×
“, 2014) and, in combination with ER antagonists, in HR breast cancer (Finn et al., 2015; Sledge et al., 2017).”
InfluentialCDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236 · cited 8×
“Nevertheless, independent studies of numerous Rb-positive tumor types have shown that most do show some degree of sensitivity to CDK4/6 inhibitors (CDK4/6i) (Baughn et al., 2006; Choi et al., 2012; Finn et al., 2009; Fry et al., 2004; Kennedy et al., 2015; Marzec et al., 2006; Puyol et al., 2010; Rader et al., 2013; Y…”
InfluentialGelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Self-citationSpectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers
Jirawatnotai, S., Hu, Y., Michowski, W., Elias, J. E., Becks, L., Bienvenu, F., Zagozdzon, A., Goswami, T., Wang, Y. E., Clark, A. B., et al. (2011) · Nature · doi:10.1038/nature10155 · Cited by 333
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
Wiedemeyer, W. R., Dunn, I. F., Quayle, S. N., Zhang, J., Chheda, M. G., Dunn, G. P., Zhuang, L., Rosenbluh, J., Chen, S., Xiao, Y., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001613107 · Cited by 223
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
Dual Inactivation of RB and p53 Pathways in RAS-Induced Melanomas
Bardeesy, N., Bastian, B. C., Hezel, A., Pinkel, D., DePinho, R. A., & Chin, L. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.6.2144-2153.2001 · Cited by 166
Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0387 · Cited by 114
Morschhauser, F., Bouabdallah, K., Stilgenbauer, S., Thieblemont, C., Wolf, M., de Guibert, S., Zettl, F., Hahka-Kemppinen, M., Xiaohui Wang, D., Brueck, P., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3067.3067 · Cited by 20
Self-citation
Cited by
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Exploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
Senescent Cells in Cancer Therapy: Friends or Foes?
Wang, B., Kohli, J., & Demaria, M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.004 · Cited by 508
Metadata
- Authors
- Gong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M., Dempsey, J., Zeng, Y., Torres, R., Boehnke, K., Mur, C., Marugán, C., Baquero, C., Yu, C., Bray, S. M., Wulur, I. H., Bi, C., Chu, S., Qian, H.-R., Iversen, P. W., Merzoug, F. F., Ye, X. S., Reinhard, C., De Dios, A., Du, J., Caldwell, C. W., Lallena, M. J., Beckmann, R. P., & Buchanan, S. G.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-12
- Volume
- 32
- Issue
- 6
- Pages
- 761-776.e6
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2775307310
- Cited by
- 236
- References
- 24
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.